Gilead's hep C meds keep churning, but execs see need for deals as U.S. sales slow

Gilead Sciences ($GILD) and its hep C juggernaut kept rolling in Q4, churning out street-beating sales of $4.9 billion. But it took strong growth overseas to overcome an expected falloff for Sovaldi and Harvoni in the U.S. While Gilead execs say there's lots of growth left in the hep C market, they acknowledged Tuesday that the company needs to be looking for M&A opportunities in areas such as oncology. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.